Corvus Pharmaceuticals' Soquelitinib Shows Durable Remissions and Safety in Atopic Dermatitis Phase 1 Trial
Phase 1 Data Reveal Drug-Free Remissions and Improved Immune Markers
Corvus Pharmaceuticals (NASDAQ: CRVS) today presented compelling final results from its Phase 1 trial of soquelitinib in moderate-to-severe atopic dermatitis at the Society for Investigative Dermatology (SID) Annual Meeting. The data point to a potential paradigm shift for patients, with evidence of durable disease control after stopping therapy and a unique immunologic profile not seen with current treatments.
Durable Efficacy After Discontinuation: No Rebound, Fewer Limitations
The soquelitinib trial enrolled 72 patients who had failed at least one prior therapy. In both main efficacy groups—those who took 200 mg twice daily—the percentage of patients achieving major skin clearance targets remained high even after treatment cessation, a marked contrast to typical relapse rates on existing oral or injectable drugs.
| Cohort | Dose/Duration | EASI 75 | EASI 90 | IGA 0/1 |
|---|---|---|---|---|
| Cohort 3 | 200 mg BID, 28 days | 50% | 8% | 25% |
| Cohort 4 | 200 mg BID, 56 days | 75% | 25% | 33% |
Importantly, across all cohorts, no significant safety concerns emerged, and adverse events in the soquelitinib and placebo groups were both 41.7%, all mild or moderate. No severe cases or treatment-limiting toxicity occurred.
Biomarker Evidence Confirms Mechanism and Enhanced Treg Response
Researchers observed a meaningful translation of soquelitinib's immunologic intent into patient results. The treatment selectively inhibited ITK, suppressing inflammatory Th2 and Th17 cell signaling—blocking cytokines tied to disease flare-ups (IL-4, IL-5, IL-13, IL-17)—and promoted a switch toward regulatory T cells (Tregs), which are crucial for immune tolerance. These improvements persisted through the drug-free period, suggesting the potential for lasting remissions.
- Dose-dependent reduction in Th2 cell activation
- Decreases in inflammatory cytokines (IL-4, IL-5, IL-13) measured in serum
- Increase in Treg cells (CD4+, Foxp3+, CD25Hi) both on treatment and post-treatment
- Downregulation of JAK1 and STAT6, upregulation of SOCS3, supporting the anti-inflammatory profile
Favorable Safety: No Severe Events, Comparable to Placebo
Across all patient groups, soquelitinib was well-tolerated, with no significant lab abnormalities. The side effect profile paralleled placebo, reflecting the targeted nature of the therapy and lack of broad immunosuppression. This is particularly notable for a systemic oral immunomodulator in this patient population.
Clinical Implications: New Hope for Resilient and Refractory Cases
The durability of clinical responses—even after brief dosing periods—is especially impressive compared to standard systemic treatments, which often require continuous dosing to prevent rapid relapse. The results support further development not just for atopic dermatitis, but potentially for other autoimmune and inflammatory conditions.
Next Steps: Phase 2 Enrollment Underway, More Data Expected This Year
Corvus is already enrolling a larger, 200-patient Phase 2 SIERRA1 trial to confirm these results, as well as supporting studies in China. These trials will further define dosing, durability, and broader applicability. Investor and analyst presentations occur today at 1:30 pm ET, and detailed slide decks are available on the Corvus website.
Key Takeaway for Readers
For patients, clinicians, and investors, soquelitinib’s profile—durable remission, strong biomarker confirmation, and an outstanding safety showing—offers a distinctive approach in a crowded field of atopic dermatitis therapies. While it’s still early, the data justify close attention as this program advances, especially for those interested in next-generation immune therapies with long-term control potential without chronic dosing.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI